“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
Launch of the first network of ephemeral laboratories in Las Vegas powered by Alcala Laboratories
NOT DISTRIBUTING TO NEWSWIRE SERVICES IN THE UNITED STATES OR BROADCASTING IN THE UNITED STATES
TORONTO, August 11, 2020 (GLOBE NEWSWIRE) – QuestCap Inc. (“QuestCap”) (CSE: QSC; FRA: 34C1) is pleased to announce that you have signed a binding Letter of Intent (LOI) to obtain one hundred of the collection sites founded in Las Vegas, LLC. 20 million questcap Inc. shares with an assigned price of C$0.15 consistent with non-unusual action, due diligence theme, final agreement and very final standard conditions. No intermediary fees were paid for this transaction.
Collection Sites, LLC has introduced COVID-19 testing in collaboration with Alcala Testing and Analysis Services, a highly complex laboratory registered through CLIA founded in San Diego, California. Alcala is an expert identified in the COVID-19 immediate laboratory test box.
“Now is the time to expand the verification environment so that everyone has accurate and affordable verification sites so they can live, lead and return to the charts with confidence,” says Tim Shelburn, CEO of Collection Sites, LLC. “We are pleased to work with our partner lab, Alcala, to identify emerging verification centers across the United States. We try to identify criteria and protocols so that everyone can check before going to paint, at school or socialize,” Shelburn says.
These new testing centers will provide convenient access to antibody and antigen testing with insurance policy options. Appointments and invoices will be processed through an online portal www.testbeforeyougo.com to restrict contact problems at sites. “The centers will offer emergency testing of COVID-19 FDA antigens and antibodies. We are in convenient locations in several cities that are easily accessible and quick and discreet testing modalities,” said Doug Sommerville, CEO of QuestCap, which oversees strategy development.
The first phase of testing is the creation of 11 ephemeral laboratories, also known as “drawing centers”, which can jointly administer 5,500 consistent tests per day, with the ability to analyze 154,000 tests consistent with month. The first site opened in Las Vegas on August 8, 2020. Other sites are expected to open Las Vegas, as well as Arizona, Texas and Indiana in the coming weeks. Drawing centers will be located in shopping malls, grocery malls, gyms, pharmacies, stadiums, on-site in small businesses, real estate offices, law firms and schools. The moment phase, which is expected to be introduced in the fall of 2020, will come with cellular contextual laboratories to allow access to those who do not have transportation or who cannot travel.
Antibody and antigen tests take 8 to 10 minutes to administer and recover qualified laboratory effects on the same day. The effects can be communicated by SMS or email, and may be accompanied by a smart fitness certificate, an Alcala iPhone app, and a HIPPA-compatible Android owner.
The network of ephemeral laboratories will use Glenco’s patented protocols and protocols to verify that Americans evolved through Glenco Medical’s Dr. Glenn Copeland, a company in which QuestCap holds a 30% stake. Dr. Copeland is also Director, President and CEO of Glenco Medical. They come with medical screening protocols for individual physical safety. Screening will include temperature and symptom controls, as well as SERological controls of COVID19 antibodies.
“We appreciate the ambitious and courageous leadership assumed by the team in Las Vegas,” says Dr. Copeland. “We are committed to ensuring that lab testing protocols are designed for businesses, businesses, and malls to deal responsibly with The Truth of Las Vegas,” says Dr. Copeland.
For more information about the pop-up lab, sites, and available lab, visit: www.testbeforeyougo.com
About QuestCap Inc. QuestCap Inc. (CSE: QSC; FRA: 34C1) is an investment company that has a social effect. Seeks, secures and budgets for the science, generation and identified responses that have an effect on our global network today.
QuestCap’s control team is complemented by a panel of global advisors that provide expertise across all sectors and geographies. This panel includes eminent immunologists Dr. Lawrence Steinman and Dr. Glenn Copeland, who have forty-five years of experience in orthopedic treatment, foot and ankle care, and sports medicine.
QuestCap budgets a variety of entities in exchange for predetermined royalties or distributions or acquires all or part of one or more companies, portfolios or other assets.
For information, contact:
Doug Sommerville, CEO [email protected] 416-301-5418
For U.S. media inquiries, contact: Veronica [email protected]
Caution related to prospective information
This press release comprises “prospective data” within the meaning of applicable Canadian securities law. Prospective data includes, but is not limited to, statements related to the proposal to obtain Collection Sites LLC, the proposed evidence and revenue to be earned through Collection Sites LLC; QuestCap’s search for investment opportunities; and the potential benefits or returns of those investments. As a general rule, prospective data would possibly be known through the use of forward-looking terms such as “forecast”, “expect” or “do not expect”, “expect”, “budget”, “planned” “estimates”, “anticipates”, “anticipates” or “does not anticipate” or “believe” or variants of one’s words and expressions or implies that certain actions, occasions or effects are ‘possibly’, ‘they can just’ , ‘would’, ‘also be just’ or ‘will be taken’ or “will be achieved”. Prospective data are subject to known and unknown risks, insecurities and other points that would possibly cause the Actual Effects, Point of Activity, Functionality or Achievements of the Company, as applicable, to differ materially from those expressed or implied through such prospects. Data. While the Company has attempted to identify vital points that may also cause the actual effects to differ materially from the content in the prospective data, there may be other points that cause the effects to not be as expected, estimated or expected. . It cannot be ensured that this data proves to be accurate, as actual effects and long-term occasions may differ materially from those expected in those statements. As a result, readers deserve not to place undue reliance on forward-looking data. The Company does not undertake to update any forward-looking data, in accordance with applicable securities laws.
NEITHER THE CANADIAN STOCK EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS BEEN REVIEWED OR ACCEPTS LIABILITY FOR THE FITNESS OR ACCURACY OF THIS RELEASE.